GCM
LYEL icon

Gladius Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Gladius Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-348
Closed -$22.1K – 419
2023
Q2 		$22.1K Sell
348
-202
-37% -$11.2K ﹤0.01% 296
2023
Q1 		$26K Buy
+550
New +$29.4K ﹤0.01% 304

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

Gladius Capital Management's LYEL Position: Q3 2023 in Review

Gladius Capital Management sold out of Lyell Immunopharma (LYEL) in Q3 2023, closing a stake of 348 shares — an estimated $22.1K sold.

Gladius Capital Management first reported a position in LYEL in Q1 2023 and held it in 2 quarters. The position peaked at $26K in Q1 2023. 106 funds tracked by Wall St. Rank hold LYEL as of Q3 2023.

  • Gladius Capital Management reported no remaining Lyell Immunopharma position as of Q3 2023 after selling out during the quarter.
  • Gladius Capital Management sold 348 Lyell Immunopharma shares in Q3 2023, an estimated $22.1K.
  • Gladius Capital Management first reported a position in Lyell Immunopharma in Q1 2023 and held it in 2 quarters.
  • Gladius Capital Management's Lyell Immunopharma position peaked at $26K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.